Sarepta Therapeutics
SRPT
17.50
+0.19
+1.10%
Sarepta Therapeutics
US · SRPT
#2853 by market cap
Listed 1970
17.50
+0.19
+1.10%
Live - 5344 symbols - heartbeat 480s ago
· 2026-10-08 04:00
Pre-market
17.36
-0.80%
After-hours
17.69
+1.09%
Overnight
17.62
+0.69%
- Market cap
- 1.85B
- P/E (TTM)i
- -11.15
- P/Bi
- 1.21
- EPSi
- -7.13
- Div yieldi
- 0.00%
- 52W posi
- 28%
Reader sentiment
Are you bullish or bearish on SRPT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -1.01, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +15.58% YoY
Margins
- Gross margin
- 61.81%
- Operating margin
- -29.92%
- Net margin
- -32.45%
Key ratios & quality
- Enterprise valuei
- 1.75B
- Altman Z-Scorei
- -1.01
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 301.03M | 380.83M | 540.10M | 701.89M | 933.01M | 1.24B | 1.90B | 2.20B |
| Gross profit | 266.84M | 324.25M | 476.72M | 604.84M | 793.02M | 1.09B | 1.58B | 1.36B |
| Selling & admin expenses | 207.76M | 284.81M | 317.88M | 282.66M | 451.42M | 481.87M | 557.87M | 491.72M |
| Research & development | 401.84M | 560.91M | 722.34M | 771.18M | 877.09M | 877.39M | 804.52M | 1.52B |
| Operating profit | -343.63M | -522.32M | -564.16M | -449.71M | -536.20M | -267.82M | 218.08M | -657.77M |
| Pretax profit | -362.61M | -713.88M | -553.07M | -418.95M | -689.96M | -520.10M | 260.77M | -702.23M |
| Tax | -692.00K | 1.20M | 1.06M | -168.00K | 13.53M | 15.88M | 25.54M | 11.19M |
| Net profit | -361.92M | -715.08M | -554.13M | -418.78M | -703.49M | -535.98M | 235.24M | -713.41M |
| Basic EPS | -5 | -10 | -7 | -5 | -8 | -6 | 2 | -7 |
| Diluted EPS | -5.46 | -9.71 | -7.11 | -5.15 | -8.03 | -5.80 | 2.34 | -7.13 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 744.86M | 611.09M | 399.36M | 442.93M | 730.80M | 401.25M |
| Gross profit | 607.29M | 458.53M | 248.58M | 44.23M | 622.04M | 251.87M |
| Selling & admin expenses | 133.63M | 137.90M | 91.89M | 128.30M | 108.95M | 107.60M |
| Research & development | 773.45M | 204.39M | 218.89M | 325.34M | 153.96M | 91.26M |
| Operating profit | -300.39M | 115.58M | -62.88M | -410.08M | 358.43M | 52.29M |
| Pretax profit | -383.52M | 153.64M | -194.05M | -278.30M | 343.17M | -1.75M |
| Tax | 63.99M | -43.25M | -14.10M | 4.55M | 12.22M | 3.14M |
| Net profit | -447.51M | 196.89M | -179.95M | -282.85M | 330.96M | -4.89M |
| Basic EPS | -5 | 2 | -2 | -4 | 3 | 0 |
| Diluted EPS | -4.60 | 1.89 | -1.80 | -3.93 | 2.88 | -0.05 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.43B | 1.47B | 2.49B | 2.60B | 2.56B | 2.58B | 3.07B | 2.54B |
| Cash & ST investments | 1.17B | 1.12B | 1.94B | 2.12B | 1.99B | 1.68B | 1.35B | 939.65M |
| Inventory | 125.45M | 171.38M | 231.96M | 186.21M | 203.97M | 322.86M | 749.96M | 914.74M |
| Total assets | 1.64B | 1.82B | 2.98B | 3.15B | 3.13B | 3.26B | 3.96B | 3.35B |
| Total current liabilities | 173.69M | 264.77M | 416.03M | 452.73M | 619.60M | 653.66M | 731.68M | 1.10B |
| Short-term debt | -- | -- | -- | 15.05M | 15.49M | 123.33M | 13.47M | 11.39M |
| Long-term debt | 420.55M | 681.90M | 992.49M | 1.10B | 1.54B | 1.13B | 1.14B | 828.97M |
| Total liabilities | 609,799,000.00 | 1,004,635,000.00 | 2,222,959,000.00 | 2,219,965,000.00 | 2,743,416,000.00 | 2,405,239,000.00 | 2,435,431,000.00 | 2,209,081,000.00 |
| Total equity | 1.03B | 818.19M | 761.76M | 928.01M | 384.95M | 859.34M | 1.53B | 1.14B |
| Retained earnings | -1.58B | -2.29B | -2.85B | -3.21B | -3.91B | -4.45B | -4.21B | -4.88B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 2.43B | 2.66B | 2.72B | 2.54B | 2.31B | 2.22B |
| Cash & ST investments | 522.76M | 800.14M | 850.99M | 939.65M | 653.19M | 788.49M |
| Inventory | 941.43M | 994.04M | 1.08B | 914.74M | 1.00B | 904.27M |
| Total assets | 3.47B | 3.68B | 3.49B | 3.35B | 3.18B | 3.19B |
| Total current liabilities | 605.59M | 919.95M | 921.43M | 1.10B | 499.16M | 502.91M |
| Short-term debt | -- | -- | -- | 11.39M | -- | -- |
| Long-term debt | 1.14B | 1.14B | 1.04B | 828.97M | 838.16M | 847.62M |
| Total liabilities | 2,322,664,000.00 | 2,322,429,000.00 | 2,173,317,000.00 | 2,209,081,000.00 | 1,673,832,000.00 | 1,660,714,000.00 |
| Total equity | 1.14B | 1.36B | 1.32B | 1.14B | 1.51B | 1.53B |
| Retained earnings | -4.66B | -4.46B | -4.64B | -4.88B | -4.55B | -4.55B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -388.66M | -456.46M | 107.47M | -443.17M | -325.35M | -500.99M | -205.79M | -205.48M |
| Depreciation & amortization | 12.25M | 24.50M | 26.91M | 38.02M | 41.86M | 44.40M | 37.72M | 44.52M |
| Free cash flow | -449.82M | -516.09M | 25.26M | -483.97M | -357.60M | -588.34M | -352.74M | -315.33M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 513.41M | 365.35M | 312.05M | 548.53M | -- | 0 | 0 | -5.01M |
| Ending cash balance | 370.83M | 843.65M | 1.51B | 2.13B | 985.80M | 444.01M | 1.12B | 814.41M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -583.44M | 261.34M | -14.59M | 131.21M | -202.68M | 197.07M |
| Depreciation & amortization | 9.98M | 10.84M | 18.45M | 5.25M | 10.59M | 10.41M |
| Free cash flow | -629.33M | 229.78M | -43.26M | 127.48M | -205.76M | 196.52M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 20.00M | 0 | -- | -- |
| Ending cash balance | 256.45M | 526.18M | 626.20M | 814.41M | 477.58M | 581.27M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -39.74 | -77.29 | -70.15 | -49.57 | -107.16 | -86.15 | 19.71 | -53.47 |
| ROA %i | -24.54 | -41.28 | -23.05 | -13.66 | -22.42 | -16.77 | 6.51 | -19.51 |
| ROIC %i | -25.13 | -46.52 | -30.31 | -18.23 | -33.03 | -27.55 | 7.30 | -28.20 |
| 5-year avg ROE %i | -61.10 | -65.58 | -59.52 | -49.15 | -68.78 | -78.06 | -58.66 | -55.33 |
| EBIT margin %i | -109.26 | -179.40 | -91.30 | -50.64 | -68.24 | -40.06 | 14.68 | -30.21 |
| FCF / sales %i | -- | -- | 4.68 | -- | -- | -- | -- | -- |
| Current ratioi | 8.21 | 5.55 | 5.97 | 5.75 | 4.13 | 3.95 | 4.20 | 2.32 |
| Quick ratioi | 7.13 | 4.61 | 5.00 | 5.06 | 3.63 | 3.23 | 2.74 | 1.33 |
| Debt / assetsi | 25.61 | 40.03 | 35.95 | 36.64 | 51.70 | 42.79 | 33.89 | 31.04 |
| LT debt / equityi | 40.74 | 89.18 | 140.84 | 122.67 | 416.12 | 148.19 | 87.03 | 90.16 |
| Interest coveragei | -9.76 | -22.28 | -8.23 | -5.60 | -11.96 | -22.63 | 15.18 | -17.41 |
| Revenue CAGR (3Y) %i | 521.66 | 312.62 | 51.74 | 32.60 | 34.81 | 32.04 | 39.42 | 33.06 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -23.61 | -4.76 | -21.37 | -53.47 | 4.91 | -9.48 |
| ROA %i | -7.43 | -1.63 | -7.66 | -19.51 | 1.96 | -3.98 |
| ROIC %i | -12.05 | -3.33 | -11.30 | -28.20 | 3.16 | -4.26 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -6.51 | -0.20 | -9.55 | -30.21 | 3.65 | -3.00 |
| FCF / sales %i | -- | -- | -- | -- | 4.96 | 3.80 |
| Current ratioi | 4.02 | 2.89 | 2.95 | 2.32 | 4.63 | 4.42 |
| Quick ratioi | 2.06 | 1.53 | 1.51 | 1.33 | 2.41 | 2.44 |
| Debt / assetsi | 38.78 | 36.79 | 35.79 | 31.04 | 32.61 | 32.80 |
| LT debt / equityi | 117.59 | 99.74 | 94.70 | 90.16 | 68.88 | 68.45 |
| Interest coveragei | -7.77 | -0.26 | -10.58 | -17.41 | 1.44 | -0.83 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Phosphorodiamidate morpholino oligomer (PMO) product revenues, net is the largest reported line at 57.46% of revenue, across 3 reported segments.
- ELEVIDYS product revenues, net follows at 24.45%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Phosphorodiamidate morpholino oligomer (PMO) product revenues, net57.46%
ELEVIDYS product revenues, net24.45%
Collaboration and other18.08%
Quote time 2026-10-08 04:00:03 · For reference only, not investment advice and not tailored to your situation.